EVLO - Evelo Biosciences Inc Stock Price, Fair Value and News

Market Closed

EVLO Stock Valuation Analysis

Valuation

Max Portfolio %

EVLO Price Action

EVLO RSI Chart

EVLO Stock Valuation Analysis

Valuation

Max Portfolio %

EVLO Valuation

EVLO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

EVLO Fundamentals

EVLO Revenue

EVLO Earnings

EVLO Profitability

EVLO Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2019	2.0M	2.1M	1.6M	1.0M
2018	0	0	0	1.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Evelo Biosciences Inc

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Balkrishan Gill Ph.D.
WEBSITE	evelobio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	66